Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02720120
Registration number
NCT02720120
Ethics application status
Date submitted
22/03/2016
Date registered
25/03/2016
Date last updated
28/03/2016
Titles & IDs
Public title
A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Query!
Scientific title
A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response
Query!
Secondary ID [1]
0
0
2004-002132-26
Query!
Secondary ID [2]
0
0
WA18230
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ocrelizumab
Treatment: Drugs - Placebo
Experimental: Part 1: Ocrelizumab 1000 mg - Participants will receive single IV infusion of ocrelizumab 1000 mg.
Experimental: Part 1: Ocrelizumab 1500 mg - Participants will receive single IV infusion of ocrelizumab 1500 mg.
Experimental: Part 1: Ocrelizumab 2000 mg - Participants will receive single IV infusion of ocrelizumab 2000 mg.
Experimental: Part 1: Ocrelizumab 400 mg - Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)
Placebo Comparator: Part 1: Placebo - Participants will receive single IV infusion of placebo matched to ocrelizumab.
Experimental: Part 2: Ocrelizumab 1000 mg - Participants will receive single IV infusion of ocrelizumab 1000 mg.
Experimental: Part 2: Ocrelizumab 1500 mg - Participants will receive single IV infusion of ocrelizumab 1500 mg.
Experimental: Part 2: Ocrelizumab 400 mg - Participants will receive single IV infusion of ocrelizumab 400 mg.
Treatment: Drugs: Ocrelizumab
Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Treatment: Drugs: Placebo
Participants will receive single IV infusion of placebo.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants with Adverse Events (AEs) or Serious AEs (SAEs)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline up to approximately 7.25 years
Query!
Primary outcome [2]
0
0
Percentage of Participants with Anti-Ocrelizumab Antibodies
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline up to approximately 7.25 years
Query!
Secondary outcome [1]
0
0
Percentage of Participants with American College of Rheumatology (ACR) 20%, 50%, and 70% (ACR20/50/70) Response at Week 24
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [2]
0
0
Disease Activity Score at Week 24
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Week 24
Query!
Secondary outcome [3]
0
0
Percentage of Participants achieving European League Against Rheumatism (EULAR) Response at Week 24
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Week 24
Query!
Secondary outcome [4]
0
0
Maximum Plasma Concentration (Cmax) of Ocrelizumab
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)
Query!
Secondary outcome [5]
0
0
Time to Blood B-Cell Depletion
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline up to approximately 7.25 years
Query!
Secondary outcome [6]
0
0
Terminal Elimination Half-Life (t1/2) of Ocrelizumab
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)
Query!
Secondary outcome [7]
0
0
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity AUC(0-inf) of Ocrelizumab
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)
Query!
Secondary outcome [8]
0
0
Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration AUC(0-last) of Ocrelizumab
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)
Query!
Secondary outcome [9]
0
0
Time to Maximum Observed Plasma Concentration (Tmax) of Ocrelizumab
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)
Query!
Secondary outcome [10]
0
0
Terminal Rate Constant of Ocrelizumab
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)
Query!
Secondary outcome [11]
0
0
Systemic Clearance (CL) of Ocrelizumab
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)
Query!
Secondary outcome [12]
0
0
Mean Residence Time (MRT) of Ocrelizumab
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)
Query!
Secondary outcome [13]
0
0
Steady State Volume of Distribution (Vss) of Ocrelizumab
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)
Query!
Secondary outcome [14]
0
0
Duration of Blood B-Cell Depletion
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Baseline up to approximately 7.25 years
Query!
Eligibility
Key inclusion criteria
- Moderate to severe RA for at least 6 months
- Positive serum rheumatoid factor (>/= 20 international units per milliliter)
- Current treatment with RA on an outpatient basis
- Treatment failure with one disease modifying anti-rheumatic drug (DMARD) or biologic,
but have not failed more than six of these agents including methotrexate
- Current treatment with methotrexate for at least 12 weeks, at a stable dose
- Use of highly effective contraception.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Rheumatic autoimmune disease or inflammatory joint disease, other than RA
- Concurrent treatment with any disease-modifying anti-rheumatic drug (DMARD) (other
than methotrexate) or any anti-tumor necrosis factor (TNF) -alfa or other biologic
therapy
- Treatment with any other investigational drug within 4 weeks of screening
- Previous treatment with cell-depleting therapies, IV gamma-globulin, intra-articular
or parenteral corticosteroids, and receipt of live/attenuated vaccine prior to
screening
- Previous treatment with rituximab or any other anti-cluster of differentiation 20
(CD20) agent
- History of severe allergic or anaphylactic reactions to humanized monoclonal
antibodies
- Known active bacterial, viral or fungal infections
- History of active tuberculosis and primary or secondary immunodeficiency
- History of concomitant diseases such as cardiovascular disease, nervous system,
pulmonary disease, renal, hepatic, endocrine or gastrointestinal disorders
- Pregnancy or lactation.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
175
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
- Darlinghurst
Query!
Recruitment hospital [2]
0
0
- Adelaide
Query!
Recruitment hospital [3]
0
0
- Melbourne
Query!
Recruitment hospital [4]
0
0
- Perth
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
5041 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
6979 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Gent
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Leuven
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
Alberta
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Ontario
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Quebec
Query!
Country [6]
0
0
Netherlands
Query!
State/province [6]
0
0
Amsterdam
Query!
Country [7]
0
0
New Zealand
Query!
State/province [7]
0
0
Auckland City
Query!
Country [8]
0
0
New Zealand
Query!
State/province [8]
0
0
Auckland
Query!
Country [9]
0
0
Russian Federation
Query!
State/province [9]
0
0
Moscow
Query!
Country [10]
0
0
Russian Federation
Query!
State/province [10]
0
0
Saint-Petersburg
Query!
Country [11]
0
0
Russian Federation
Query!
State/province [11]
0
0
St Petersburg
Query!
Country [12]
0
0
Russian Federation
Query!
State/province [12]
0
0
St. Petersburg
Query!
Country [13]
0
0
Spain
Query!
State/province [13]
0
0
Cadiz
Query!
Country [14]
0
0
Spain
Query!
State/province [14]
0
0
La Coruña
Query!
Country [15]
0
0
Spain
Query!
State/province [15]
0
0
Madrid
Query!
Country [16]
0
0
Spain
Query!
State/province [16]
0
0
Tenerife
Query!
Country [17]
0
0
Spain
Query!
State/province [17]
0
0
Barcelona
Query!
Country [18]
0
0
Spain
Query!
State/province [18]
0
0
Granada
Query!
Country [19]
0
0
Spain
Query!
State/province [19]
0
0
Sevilla
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Valencia
Query!
Country [21]
0
0
United Kingdom
Query!
State/province [21]
0
0
Aberdeen
Query!
Country [22]
0
0
United Kingdom
Query!
State/province [22]
0
0
Cambridge
Query!
Country [23]
0
0
United Kingdom
Query!
State/province [23]
0
0
Derby
Query!
Country [24]
0
0
United Kingdom
Query!
State/province [24]
0
0
Leeds
Query!
Country [25]
0
0
United Kingdom
Query!
State/province [25]
0
0
Liverpool
Query!
Country [26]
0
0
United Kingdom
Query!
State/province [26]
0
0
London
Query!
Country [27]
0
0
United Kingdom
Query!
State/province [27]
0
0
Maidstone
Query!
Country [28]
0
0
United Kingdom
Query!
State/province [28]
0
0
Newcastle Upon Tyne
Query!
Country [29]
0
0
United Kingdom
Query!
State/province [29]
0
0
Norwich
Query!
Country [30]
0
0
United Kingdom
Query!
State/province [30]
0
0
Salford
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
Torquay
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
West Midlands
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is in two parts and will evaluate the safety, tolerability and efficacy of
escalating single intravenous (IV) doses of ocrelizumab compared with placebo in combination
with methotrexate in participants with moderate to severe RA. Part 1 is the dose-escalation
study, at one of the following dose levels of ocrelizumab [400, 1000, 1500, and 2000
milligrams (mg)]. In Part 2, participants will be randomized to explore tolerability and
efficacy of doses which have been shown to be tolerated in Part 1.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02720120
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02720120
Download to PDF